<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803073</url>
  </required_header>
  <id_info>
    <org_study_id>L16-116</org_study_id>
    <nct_id>NCT02803073</nct_id>
  </id_info>
  <brief_title>Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction</brief_title>
  <official_title>Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After A Recent Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of testosterone replacement in
      hypogonadal men on exercise tolerance and cardiac rehabilitation after an acute myocardial
      infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Testosterone deficiency can decrease muscle strength. The researchers will replace
      testosterone in hypogonadal men undergoing rehabilitation exercises after heart attack.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic Equivalent</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Acute Myocardial Infarction: Rehabilitation Phase</condition>
  <arm_group>
    <arm_group_label>Testosterone Replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will receive 0.5 ml (100 mg) testosterone cypionate Intramuscular injections each week for 11 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the control group will receive intramuscular normal saline injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Testosterone Cypionate Intramuscular injections will be administered weekly</description>
    <arm_group_label>Testosterone Replacement</arm_group_label>
    <other_name>testosterone cypionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline Intramuscular injections will be administered weekly</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All men status-post Myocardial Infarction or Non-ST Elevation-Acute Coronary Syndrome
             within the last 3-8 weeks enrolling in the cardiac rehabilitation program at Mission
             Fitness-Medical Center Hospital.

          2. Baseline free testosterone levels less than age-specific normal values.

          3. Males 18 years and older

        Exclusion Criteria:

          1. Prostate Specific Antigen greater than age based, ethnic-specific cut points (see
             Appendix), history of metastatic prostate cancer or symptoms suggestive of severe
             Benign Prostatic Enlargement.

          2. Current use of testosterone, clomiphene or over the counter testosterone boosters

          3. Patients initiating cardiac rehabilitation 8+ weeks after MI or Non-ST Elevation-Acute
             Coronary Syndrome

          4. Congestive heart failure, New York Heart Association class IV

          5. Life expectancy less than 1 year,

          6. Baseline hematocrit of &gt;50%

          7. Allergic reactions to testosterone or testosterone vehicle (i.e. cotton seed oil,
             etc.)

          8. Physical inability to participate in rehabilitation program (examples: severe
             claudication, massive obesity, etc.)

          9. Participation in any other concurrent clinical trial, use of an investigational agent
             or therapeutic regimen within 30 days of study

         10. Patients formerly diagnosed with obstructive sleep apnea.

         11. Patients using opiate analgesics

         12. Patients with aspartate aminotransferase/alanine aminotransferase values more than 3
             times normal

         13. History of Deep venous thrombosis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama Mukarram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig W Spellman, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandeep Dhindsa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University Health Sciences Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig W Spellman, DO</last_name>
    <phone>4327035347</phone>
    <email>craig.spellman@ttuhsc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mission Fitness-Medical Center Hospital</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Baldomero, DNP</last_name>
      <phone>432-640-1472</phone>
      <email>RBaldomero@echd.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

